Publication | Closed Access

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Healthy SubjectsOral Gw572016PharmacologyPharmacotherapyMedicineDual Egfr-erbb2 InhibitorPharmacokineticsTranslational Pharmacology